GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Henley CEO identifies Malta as few European nations seeing centi-millionaire population surge
The firm describes centi-millionaires as individuals with liquid investable assets of USD 100 million or more.
Clampdown on tax-dodgers yielding results as Government collects additional €500 million in dues
Revenues increased even though no new taxes were introduced
Malta-based Game Lounge unveils Employee Value Proposition initiative
This strategy includes regular training sessions, workshops, access to skill-enhancing educational materials and a four-day summer work week.
Dear CEO: MFSA appeals to credit institutions for more transparency when offering green products
In its review, the MFSA noted a growing range of green products being introduced to meet market demand.
